BAMF
BMRN icon

BI Asset Management Fondsmaeglerselskab’s BioMarin Pharmaceuticals BMRN Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,585
Closed -$629K – 627
2025
Q4 		$629K Sell
10,585
-204
-2% -$11.1K 0.01% 588
2025
Q3 		$584K Sell
10,789
-3,282
-23% -$188K 0.01% 585
2025
Q2 		$773K Buy
14,071
+1,376
+11% +$81K 0.01% 538
2025
Q1 		$897K Sell
12,695
-15,366
-55% -$1.03M 0.01% 457
2024
Q4 		$1.84M Buy
28,061
+1,704
+6% +$114K 0.02% 378
2024
Q3 		$1.85M Buy
26,357
+24,187
+1,115% +$2.02M 0.03% 291
2024
Q2 		$179K Sell
2,170
-3,553
-62% -$296K ﹤0.01% 566
2024
Q1 		$500K Sell
5,723
-2,820
-33% -$252K 0.01% 529
2023
Q4 		$824K Buy
8,543
+5,434
+175% +$481K 0.02% 429
2023
Q3 		$275K Hold
3,109
– – 0.01% 582
2023
Q2 		$269K Buy
3,109
+1,759
+130% +$166K 0.01% 580
2023
Q1 		$131K Sell
1,350
-4,539
-77% -$471K ﹤0.01% 652
2022
Q4 		$609K Buy
5,889
+48
+0.8% +$4.51K 0.02% 394
2022
Q3 		$495K Buy
5,841
+951
+19% +$84.7K 0.03% 281
2022
Q2 		$405K Hold
4,890
– – 0.02% 339
2022
Q1 		$377K Buy
+4,890
New +$409K 0.01% 334
2020
Q4 		– Sell
-917
Closed -$70K – 388
2020
Q3 		$70K Buy
+917
New +$92.8K ﹤0.01% 425
2020
Q1 		– Sell
-1,551
Closed -$131K – 326
2019
Q4 		$131K Sell
1,551
-2,994
-66% -$226K 0.01% 301
2019
Q3 		$306K Buy
4,545
+1,042
+30% +$80.3K 0.02% 323
2019
Q2 		$300K Buy
+3,503
New +$300K 0.01% 206

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's BMRN Position: Q1 2026 in Review

BI Asset Management Fondsmaeglerselskab sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 10,585 shares — an estimated $629K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in BMRN in Q2 2019 and held it in 20 quarters. The position peaked at $1.85M in Q3 2024. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • BI Asset Management Fondsmaeglerselskab reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 10,585 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $629K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 20 quarters.
  • BI Asset Management Fondsmaeglerselskab's BioMarin Pharmaceuticals position peaked at $1.85M in Q3 2024.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q1 2026, filed 16 Apr 2026.